HLA-A26 is a risk factor for Behçet's disease ocular lesions
How HLA-A26 modulates Behçet's disease (BD) ocular lesions such as iridocyclitis and retinochorioiditis has not been scrutinized. Ministry of Health, Labour and Welfare of Japan provided us a database of BD patients who were registered from 2003 to 2014. We selected patients who satisfied Inter...
Gespeichert in:
| Veröffentlicht in: | Modern rheumatology 2021, Vol.31 (1), p.214-218 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 218 |
|---|---|
| container_issue | 1 |
| container_start_page | 214 |
| container_title | Modern rheumatology |
| container_volume | 31 |
| creator | Kato, Hiroaki Takeuchi, Masaki Horita, Nobuyuki Ishido, Takehito Mizuki, Ryuta Kawagoe, Tatsukata Shibuya, Etsuko Yuda, Kentaro Ishido, Mizuho Mizuki, Yuki Hayashi, Takahiko Meguro, Akira Kirino, Yohei Minegishi, Kaoru Nakano, Hiroto Yoshimi, Ryusuke Kurosawa, Michiko Fukumoto, Takeshi Takeno, Mitsuhiro Hotta, Kazuki Kaneko, Takeshi Mizuki, Nobuhisa |
| description | How HLA-A26 modulates Behçet's disease (BD) ocular lesions such as iridocyclitis and retinochorioiditis has not been scrutinized.
Ministry of Health, Labour and Welfare of Japan provided us a database of BD patients who were registered from 2003 to 2014. We selected patients who satisfied International Criteria for BD and whose data for HLA-A26 was available.
Eligible 557 patients consisting of 238 men (42.7%) and 319 women (57.3%), whose median age was 38 years old (interquartile range 29-47) were analyzed. Prevalence of general ocular lesions, iridocyclitis, retinochorioiditis, and chronic lesions were 43.1%, 30.7%, 34.1%, and 17.4%, respectively. The prevalence of ocular lesions was higher among HLA-A26 carriers compared to that among HLA-A26 non-carriers with odds ratio (OR) of 2.5 (95% confidence interval (95% CI) 1.8-3.5, p |
| doi_str_mv | 10.1080/14397595.2019.1705538 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1080_14397595_2019_1705538</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>31851572</sourcerecordid><originalsourceid>FETCH-LOGICAL-c511t-621c0189f889a97925ca55f2e4cb66cf4660290262612a1614e593050e4664203</originalsourceid><addsrcrecordid>eNp9kMFKAzEQhoMotlYfQcnN09aZ7CabHARrUSsUvOg5pGmC0W23JFukT-SD-GKmtPXoYZhh5v9nmI-QS4QhgoQbrEpVc8WHDFANsQbOS3lE-tt-UQtQx4c6i3rkLKUPgJIrqU5Jr0TJkdesT24n01ExYoKGRA2NIX1Sb2zXRupz3Lv3n2_XXSc6D8mZ5Ghr142JtHEptMt0Tk68aZK72OcBeXt8eB1PiunL0_N4NC0sR-wKwdACSuWlVEbVinFrOPfMVXYmhPWVEMAUMMEEMoMCK8dVCRxcnlQMygHhu702tilF5_UqhoWJG42gtzj0AYfe4tB7HNl3tfOt1rOFm_-5Dv9nwd1OEJb534X5amMz153ZNG300SxtSFn8741fXEZryA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>HLA-A26 is a risk factor for Behçet's disease ocular lesions</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><creator>Kato, Hiroaki ; Takeuchi, Masaki ; Horita, Nobuyuki ; Ishido, Takehito ; Mizuki, Ryuta ; Kawagoe, Tatsukata ; Shibuya, Etsuko ; Yuda, Kentaro ; Ishido, Mizuho ; Mizuki, Yuki ; Hayashi, Takahiko ; Meguro, Akira ; Kirino, Yohei ; Minegishi, Kaoru ; Nakano, Hiroto ; Yoshimi, Ryusuke ; Kurosawa, Michiko ; Fukumoto, Takeshi ; Takeno, Mitsuhiro ; Hotta, Kazuki ; Kaneko, Takeshi ; Mizuki, Nobuhisa</creator><creatorcontrib>Kato, Hiroaki ; Takeuchi, Masaki ; Horita, Nobuyuki ; Ishido, Takehito ; Mizuki, Ryuta ; Kawagoe, Tatsukata ; Shibuya, Etsuko ; Yuda, Kentaro ; Ishido, Mizuho ; Mizuki, Yuki ; Hayashi, Takahiko ; Meguro, Akira ; Kirino, Yohei ; Minegishi, Kaoru ; Nakano, Hiroto ; Yoshimi, Ryusuke ; Kurosawa, Michiko ; Fukumoto, Takeshi ; Takeno, Mitsuhiro ; Hotta, Kazuki ; Kaneko, Takeshi ; Mizuki, Nobuhisa</creatorcontrib><description>How HLA-A26 modulates Behçet's disease (BD) ocular lesions such as iridocyclitis and retinochorioiditis has not been scrutinized.
Ministry of Health, Labour and Welfare of Japan provided us a database of BD patients who were registered from 2003 to 2014. We selected patients who satisfied International Criteria for BD and whose data for HLA-A26 was available.
Eligible 557 patients consisting of 238 men (42.7%) and 319 women (57.3%), whose median age was 38 years old (interquartile range 29-47) were analyzed. Prevalence of general ocular lesions, iridocyclitis, retinochorioiditis, and chronic lesions were 43.1%, 30.7%, 34.1%, and 17.4%, respectively. The prevalence of ocular lesions was higher among HLA-A26 carriers compared to that among HLA-A26 non-carriers with odds ratio (OR) of 2.5 (95% confidence interval (95% CI) 1.8-3.5, p < .001) for general ocular lesions, OR of 2.5 (95% CI 1.7-3.6, p < .001) for iridocyclitis, OR of 2.8 (95% CI 1.9-4.0, p < .001) for retinochorioiditis, and OR of 2.7 (95% CI 1.7-4.3, p < .001) for 'chronic ocular lesion following iridocyclitis or retinochorioiditis'. The HLA-A26 had a similar impact on ocular lesions between HLA-B51 positive and negative cases (Breslow-Day test, p > .05). However, the HLA-A26 had a larger impact on iridocyclitis for men compared to women (Breslow-Day test, p = .040). The male HLA-A26 carriers had higher risk of iridocyclitis with OR of 3.4 (95% CI 2.0-5.9, p < .001), while the OR for women was 1.5 (95% CI 0.9-2.6, p = .146).
HLA-A26 carriers had higher risk for iridocyclitis and retinochorioiditis. However, the impact was more prominent for men.</description><identifier>ISSN: 1439-7595</identifier><identifier>EISSN: 1439-7609</identifier><identifier>DOI: 10.1080/14397595.2019.1705538</identifier><identifier>PMID: 31851572</identifier><language>eng</language><publisher>United States: Taylor & Francis</publisher><subject>Adult ; Behcet Syndrome - genetics ; Behcet Syndrome - pathology ; eye disease ; Female ; Histocompatibility antigens class I ; HLA-A Antigens - genetics ; HLA-B51 Antigen - genetics ; Humans ; inflammation ; Male ; Middle Aged ; Odds Ratio ; posterior uveitis ; Risk Factors</subject><ispartof>Modern rheumatology, 2021, Vol.31 (1), p.214-218</ispartof><rights>2019 Japan College of Rheumatology 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c511t-621c0189f889a97925ca55f2e4cb66cf4660290262612a1614e593050e4664203</citedby><cites>FETCH-LOGICAL-c511t-621c0189f889a97925ca55f2e4cb66cf4660290262612a1614e593050e4664203</cites><orcidid>0000-0002-9488-661X ; 0000-0002-9212-7046</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31851572$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kato, Hiroaki</creatorcontrib><creatorcontrib>Takeuchi, Masaki</creatorcontrib><creatorcontrib>Horita, Nobuyuki</creatorcontrib><creatorcontrib>Ishido, Takehito</creatorcontrib><creatorcontrib>Mizuki, Ryuta</creatorcontrib><creatorcontrib>Kawagoe, Tatsukata</creatorcontrib><creatorcontrib>Shibuya, Etsuko</creatorcontrib><creatorcontrib>Yuda, Kentaro</creatorcontrib><creatorcontrib>Ishido, Mizuho</creatorcontrib><creatorcontrib>Mizuki, Yuki</creatorcontrib><creatorcontrib>Hayashi, Takahiko</creatorcontrib><creatorcontrib>Meguro, Akira</creatorcontrib><creatorcontrib>Kirino, Yohei</creatorcontrib><creatorcontrib>Minegishi, Kaoru</creatorcontrib><creatorcontrib>Nakano, Hiroto</creatorcontrib><creatorcontrib>Yoshimi, Ryusuke</creatorcontrib><creatorcontrib>Kurosawa, Michiko</creatorcontrib><creatorcontrib>Fukumoto, Takeshi</creatorcontrib><creatorcontrib>Takeno, Mitsuhiro</creatorcontrib><creatorcontrib>Hotta, Kazuki</creatorcontrib><creatorcontrib>Kaneko, Takeshi</creatorcontrib><creatorcontrib>Mizuki, Nobuhisa</creatorcontrib><title>HLA-A26 is a risk factor for Behçet's disease ocular lesions</title><title>Modern rheumatology</title><addtitle>Mod Rheumatol</addtitle><description>How HLA-A26 modulates Behçet's disease (BD) ocular lesions such as iridocyclitis and retinochorioiditis has not been scrutinized.
Ministry of Health, Labour and Welfare of Japan provided us a database of BD patients who were registered from 2003 to 2014. We selected patients who satisfied International Criteria for BD and whose data for HLA-A26 was available.
Eligible 557 patients consisting of 238 men (42.7%) and 319 women (57.3%), whose median age was 38 years old (interquartile range 29-47) were analyzed. Prevalence of general ocular lesions, iridocyclitis, retinochorioiditis, and chronic lesions were 43.1%, 30.7%, 34.1%, and 17.4%, respectively. The prevalence of ocular lesions was higher among HLA-A26 carriers compared to that among HLA-A26 non-carriers with odds ratio (OR) of 2.5 (95% confidence interval (95% CI) 1.8-3.5, p < .001) for general ocular lesions, OR of 2.5 (95% CI 1.7-3.6, p < .001) for iridocyclitis, OR of 2.8 (95% CI 1.9-4.0, p < .001) for retinochorioiditis, and OR of 2.7 (95% CI 1.7-4.3, p < .001) for 'chronic ocular lesion following iridocyclitis or retinochorioiditis'. The HLA-A26 had a similar impact on ocular lesions between HLA-B51 positive and negative cases (Breslow-Day test, p > .05). However, the HLA-A26 had a larger impact on iridocyclitis for men compared to women (Breslow-Day test, p = .040). The male HLA-A26 carriers had higher risk of iridocyclitis with OR of 3.4 (95% CI 2.0-5.9, p < .001), while the OR for women was 1.5 (95% CI 0.9-2.6, p = .146).
HLA-A26 carriers had higher risk for iridocyclitis and retinochorioiditis. However, the impact was more prominent for men.</description><subject>Adult</subject><subject>Behcet Syndrome - genetics</subject><subject>Behcet Syndrome - pathology</subject><subject>eye disease</subject><subject>Female</subject><subject>Histocompatibility antigens class I</subject><subject>HLA-A Antigens - genetics</subject><subject>HLA-B51 Antigen - genetics</subject><subject>Humans</subject><subject>inflammation</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Odds Ratio</subject><subject>posterior uveitis</subject><subject>Risk Factors</subject><issn>1439-7595</issn><issn>1439-7609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMFKAzEQhoMotlYfQcnN09aZ7CabHARrUSsUvOg5pGmC0W23JFukT-SD-GKmtPXoYZhh5v9nmI-QS4QhgoQbrEpVc8WHDFANsQbOS3lE-tt-UQtQx4c6i3rkLKUPgJIrqU5Jr0TJkdesT24n01ExYoKGRA2NIX1Sb2zXRupz3Lv3n2_XXSc6D8mZ5Ghr142JtHEptMt0Tk68aZK72OcBeXt8eB1PiunL0_N4NC0sR-wKwdACSuWlVEbVinFrOPfMVXYmhPWVEMAUMMEEMoMCK8dVCRxcnlQMygHhu702tilF5_UqhoWJG42gtzj0AYfe4tB7HNl3tfOt1rOFm_-5Dv9nwd1OEJb534X5amMz153ZNG300SxtSFn8741fXEZryA</recordid><startdate>2021</startdate><enddate>2021</enddate><creator>Kato, Hiroaki</creator><creator>Takeuchi, Masaki</creator><creator>Horita, Nobuyuki</creator><creator>Ishido, Takehito</creator><creator>Mizuki, Ryuta</creator><creator>Kawagoe, Tatsukata</creator><creator>Shibuya, Etsuko</creator><creator>Yuda, Kentaro</creator><creator>Ishido, Mizuho</creator><creator>Mizuki, Yuki</creator><creator>Hayashi, Takahiko</creator><creator>Meguro, Akira</creator><creator>Kirino, Yohei</creator><creator>Minegishi, Kaoru</creator><creator>Nakano, Hiroto</creator><creator>Yoshimi, Ryusuke</creator><creator>Kurosawa, Michiko</creator><creator>Fukumoto, Takeshi</creator><creator>Takeno, Mitsuhiro</creator><creator>Hotta, Kazuki</creator><creator>Kaneko, Takeshi</creator><creator>Mizuki, Nobuhisa</creator><general>Taylor & Francis</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0002-9488-661X</orcidid><orcidid>https://orcid.org/0000-0002-9212-7046</orcidid></search><sort><creationdate>2021</creationdate><title>HLA-A26 is a risk factor for Behçet's disease ocular lesions</title><author>Kato, Hiroaki ; Takeuchi, Masaki ; Horita, Nobuyuki ; Ishido, Takehito ; Mizuki, Ryuta ; Kawagoe, Tatsukata ; Shibuya, Etsuko ; Yuda, Kentaro ; Ishido, Mizuho ; Mizuki, Yuki ; Hayashi, Takahiko ; Meguro, Akira ; Kirino, Yohei ; Minegishi, Kaoru ; Nakano, Hiroto ; Yoshimi, Ryusuke ; Kurosawa, Michiko ; Fukumoto, Takeshi ; Takeno, Mitsuhiro ; Hotta, Kazuki ; Kaneko, Takeshi ; Mizuki, Nobuhisa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c511t-621c0189f889a97925ca55f2e4cb66cf4660290262612a1614e593050e4664203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Behcet Syndrome - genetics</topic><topic>Behcet Syndrome - pathology</topic><topic>eye disease</topic><topic>Female</topic><topic>Histocompatibility antigens class I</topic><topic>HLA-A Antigens - genetics</topic><topic>HLA-B51 Antigen - genetics</topic><topic>Humans</topic><topic>inflammation</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Odds Ratio</topic><topic>posterior uveitis</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kato, Hiroaki</creatorcontrib><creatorcontrib>Takeuchi, Masaki</creatorcontrib><creatorcontrib>Horita, Nobuyuki</creatorcontrib><creatorcontrib>Ishido, Takehito</creatorcontrib><creatorcontrib>Mizuki, Ryuta</creatorcontrib><creatorcontrib>Kawagoe, Tatsukata</creatorcontrib><creatorcontrib>Shibuya, Etsuko</creatorcontrib><creatorcontrib>Yuda, Kentaro</creatorcontrib><creatorcontrib>Ishido, Mizuho</creatorcontrib><creatorcontrib>Mizuki, Yuki</creatorcontrib><creatorcontrib>Hayashi, Takahiko</creatorcontrib><creatorcontrib>Meguro, Akira</creatorcontrib><creatorcontrib>Kirino, Yohei</creatorcontrib><creatorcontrib>Minegishi, Kaoru</creatorcontrib><creatorcontrib>Nakano, Hiroto</creatorcontrib><creatorcontrib>Yoshimi, Ryusuke</creatorcontrib><creatorcontrib>Kurosawa, Michiko</creatorcontrib><creatorcontrib>Fukumoto, Takeshi</creatorcontrib><creatorcontrib>Takeno, Mitsuhiro</creatorcontrib><creatorcontrib>Hotta, Kazuki</creatorcontrib><creatorcontrib>Kaneko, Takeshi</creatorcontrib><creatorcontrib>Mizuki, Nobuhisa</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Modern rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kato, Hiroaki</au><au>Takeuchi, Masaki</au><au>Horita, Nobuyuki</au><au>Ishido, Takehito</au><au>Mizuki, Ryuta</au><au>Kawagoe, Tatsukata</au><au>Shibuya, Etsuko</au><au>Yuda, Kentaro</au><au>Ishido, Mizuho</au><au>Mizuki, Yuki</au><au>Hayashi, Takahiko</au><au>Meguro, Akira</au><au>Kirino, Yohei</au><au>Minegishi, Kaoru</au><au>Nakano, Hiroto</au><au>Yoshimi, Ryusuke</au><au>Kurosawa, Michiko</au><au>Fukumoto, Takeshi</au><au>Takeno, Mitsuhiro</au><au>Hotta, Kazuki</au><au>Kaneko, Takeshi</au><au>Mizuki, Nobuhisa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HLA-A26 is a risk factor for Behçet's disease ocular lesions</atitle><jtitle>Modern rheumatology</jtitle><addtitle>Mod Rheumatol</addtitle><date>2021</date><risdate>2021</risdate><volume>31</volume><issue>1</issue><spage>214</spage><epage>218</epage><pages>214-218</pages><issn>1439-7595</issn><eissn>1439-7609</eissn><abstract>How HLA-A26 modulates Behçet's disease (BD) ocular lesions such as iridocyclitis and retinochorioiditis has not been scrutinized.
Ministry of Health, Labour and Welfare of Japan provided us a database of BD patients who were registered from 2003 to 2014. We selected patients who satisfied International Criteria for BD and whose data for HLA-A26 was available.
Eligible 557 patients consisting of 238 men (42.7%) and 319 women (57.3%), whose median age was 38 years old (interquartile range 29-47) were analyzed. Prevalence of general ocular lesions, iridocyclitis, retinochorioiditis, and chronic lesions were 43.1%, 30.7%, 34.1%, and 17.4%, respectively. The prevalence of ocular lesions was higher among HLA-A26 carriers compared to that among HLA-A26 non-carriers with odds ratio (OR) of 2.5 (95% confidence interval (95% CI) 1.8-3.5, p < .001) for general ocular lesions, OR of 2.5 (95% CI 1.7-3.6, p < .001) for iridocyclitis, OR of 2.8 (95% CI 1.9-4.0, p < .001) for retinochorioiditis, and OR of 2.7 (95% CI 1.7-4.3, p < .001) for 'chronic ocular lesion following iridocyclitis or retinochorioiditis'. The HLA-A26 had a similar impact on ocular lesions between HLA-B51 positive and negative cases (Breslow-Day test, p > .05). However, the HLA-A26 had a larger impact on iridocyclitis for men compared to women (Breslow-Day test, p = .040). The male HLA-A26 carriers had higher risk of iridocyclitis with OR of 3.4 (95% CI 2.0-5.9, p < .001), while the OR for women was 1.5 (95% CI 0.9-2.6, p = .146).
HLA-A26 carriers had higher risk for iridocyclitis and retinochorioiditis. However, the impact was more prominent for men.</abstract><cop>United States</cop><pub>Taylor & Francis</pub><pmid>31851572</pmid><doi>10.1080/14397595.2019.1705538</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-9488-661X</orcidid><orcidid>https://orcid.org/0000-0002-9212-7046</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1439-7595 |
| ispartof | Modern rheumatology, 2021, Vol.31 (1), p.214-218 |
| issn | 1439-7595 1439-7609 |
| language | eng |
| recordid | cdi_crossref_primary_10_1080_14397595_2019_1705538 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE |
| subjects | Adult Behcet Syndrome - genetics Behcet Syndrome - pathology eye disease Female Histocompatibility antigens class I HLA-A Antigens - genetics HLA-B51 Antigen - genetics Humans inflammation Male Middle Aged Odds Ratio posterior uveitis Risk Factors |
| title | HLA-A26 is a risk factor for Behçet's disease ocular lesions |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T16%3A15%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HLA-A26%20is%20a%20risk%20factor%20for%20Beh%C3%A7et's%20disease%20ocular%20lesions&rft.jtitle=Modern%20rheumatology&rft.au=Kato,%20Hiroaki&rft.date=2021&rft.volume=31&rft.issue=1&rft.spage=214&rft.epage=218&rft.pages=214-218&rft.issn=1439-7595&rft.eissn=1439-7609&rft_id=info:doi/10.1080/14397595.2019.1705538&rft_dat=%3Cpubmed_cross%3E31851572%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/31851572&rfr_iscdi=true |